Biotech push may help offset generic competition; some analysts skeptical
Lilly executives want to make biotech their top focus.
Lilly executives want to make biotech their top focus.
Three months after launching an initiative to boost drug-development firms in Indiana, officials at BioCrossroads have written
a report that attempts to show in detail the vast market opportunity they see.
For the last two months, two academics at Indiana University and Purdue University have been discussing how the institutions
can work together to rev up research in medicine and life sciences and, in the process, boost Indiana’s economy.
Four former top scientists at Eli Lilly and Co. have formed a Carmel-based company to develop diabetes therapies–a venture observers say has the potential to become the kind of blockbuster success BioCrossroads was built to stimulate.
Labs are nearing capacity at Strand Analytical Laboratories, which provides forensic and paternity DNA testing. In the second year of Scott Newman’s business, the former prosecutor predicts 2007 revenue will reach $4 million.